Given the ability of OVT to induce immune reactions within the tumor, the power of OVT to sensitize tumors to ICI therapy has being postulated and the synergy between OVT and PD-1 blockade has been proven in various tumor models including colon and ovarian cancer models as well as advanced melanoma patients (12–15). The gene discussed is PDCD1; the disease is melanoma.